Herbert L. Heyneker

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Epoch Biosciences, Inc. manufactures and develops molecular tools for genetic analysis. Its technology has numerous applications including the detection of inherited diseases and single nucleotide polymorphisms to identify individuals at risk for disease or adverse drug reactions and gene expression measurement. The company was founded in 1985 and is headquartered in Bothell, WA.

GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA.

Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY.

Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands.

Abeome Corp. operates as a biotechnology company. It develops therapeutic and diagnostic monoclonal antibodies (mAbs). The firm’s DiSH (Direct Selection of Hybridomas) technology offers a process for selecting and cloning desired hybridomas that produce antibodies with optimal binding characteristics. The company was founded by Richard B. Meagher in 2000 and is headquartered in Athens, GA.

GenPharm International, Inc. manufactures biopharmaceutical products. The company works towards the application of transgenic animal technology to the development of human antibody products, which are used for therapeutic uses. It was founded in 1988 and is located in San Jose, CA.

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.